慢性质子泵抑制剂使用与阻塞性肺疾病急性加重风险
基于比利时2017-2022年全国医保数据,纳入932,135例长期用药的慢性阻塞性气道疾病成人患者,采用多变量Cox模型分析。结果显示,PPI使用与急性加重风险增加相关(校正HR 1.18,95%CI 1.17-1.19),且风险随累积 defined daily dose(DDD)增加而升高。
要点
- 长期PPI使用与阻塞性气道疾病患者急性加重风险增加独立相关。
- 急性加重风险随PPI累积剂量增加呈剂量依赖性升高。
- 临床呼吸实践中应审慎评估长期PPI使用的必要性。
核心结论
- 在阻塞性肺疾病患者中,累积PPI使用与急性加重风险增加相关。
研究设计与样本
- 基于比利时2017-2022年全国医保索赔数据的回顾性队列研究,纳入932,135例长期用药的慢性阻塞性气道疾病成人患者,采用多变量Cox模型和逆概率治疗加权Cox回归分析。
主要发现
- PPI使用者416,087例(44.6%),其中过去一年累积1-28 DDDs者57,540例(13.8%),29-180 DDDs者128,017例(30.8%),181-365 DDDs者127,981例(30.8%),>365 DDDs者102,549例(24.6%)。
- 校正年龄、性别、吸烟、社会经济状态、急性加重史、短效支气管舒张剂使用、衰弱和合并症后,PPI使用与急性加重风险增加相关(校正HR 1.18,95%CI 1.17-1.19)。
- 与未使用PPI者相比,急性加重风险随累积DDDs增加而升高:≤28 DDDs HR 1.09(95%CI 1.07-1.10);≤180 DDDs HR 1.15(95%CI 1.14-1.16);≤365 DDDs HR 1.19(95%CI 1.18-1.20);>365 DDDs HR 1.25(95%CI 1.23-1.26)。
- 敏感性分析显示,该关联在50岁以下、非衰弱及理论PPI血药浓度升高的患者中更明显,而在胃食管反流病患者中短期使用无显著关联。
临床怎么用
- 呼吸科临床中应审慎评估长期PPI使用的必要性,尤其对高累积剂量者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have shown inconsistent results regarding the use of proton pump inhibitors (PPIs) and the risk on exacerbations in patients with chronic obstructive airway diseases (COADs). RESEARCH QUESTION: Is long-term PPI use associated with exacerbation risk? STUDY DESIGN AND METHODS: Using Belgian nationwide claims-based data of adult patients receiving long-term medication for COADs between 2017 and 2022, we investigated the association between PPI use and exacerbation risk using multivariable Cox models. Based on defined daily doses (DDDs) dispensed during the prior year, dose-dependent associations were assessed by inverse probability of treatment weighted Cox regression models. RESULTS: Among 932,135 included patients with COADs, 416,087 patients (44.6%) were PPI users, of whom 57,540 patients (13.8%) received 1-28 DDDs of PPIs, 128,017 patients (30.8%) received 29-180 DDDs, 127,981 patients (30.8%) received 181-365 DDDs, and 102,549 patients (24.6%) received > 365 DDDs in the previous year. Beyond age, sex, smoking, socioeconomic status, exacerbation history, short-acting bronchodilator use, frailty, and comorbidities, PPI use was associated with an increased risk of exacerbations (adjusted hazard ratio [HR], 1.18 [95% CI, 1.17-1.19]). Moreover, compared with patients who did not use PPIs, the risk of exacerbations increased with cumulative DDDs (≤ 28 DDDs: HR, 1.09 [95% CI, 1.07-1.10]; ≤ 180 DDDs: HR, 1.15 [95% CI, 1.14-1.16]; ≤ 365 DDDs: HR, 1.19 [95% CI, 1.18-1.20]; and > 365 DDDs: HR, 1.25 [95% CI, 1.23-1.26]). Sensitivity analyses indicated that the association with exacerbation risk was most pronounced in patients younger than 50 years, who were not frail, and with theoretically increased PPI plasma concentrations, and was not significant when used short-term in patients with gastroesophageal reflux disease. INTERPRETATION: Cumulative PPI use in patients with obstructive lung diseases was associated with an increase in exacerbation risk. This highlights the need to consider PPI use carefully in clinical respiratory practice.
引用
- Dehondt, Van Vaerenbergh, Verhamme, et al. Exacerbation Risk by Chronic Proton Pump Inhibitor Use in Obstructive Lung Diseases. Chest. 2026. PMID: 41548651. doi:10.1016/j.chest.2026.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。